Table 3.

Selected clinical trial with immunotherapy for advanced HCC

NCT number	Treatment	Target	Outcome	Phase
NCT02702401	Pembrolizumab vs best supportive care	PD-1	PFS, OS	Phase III
NCT02576509	Nivolumab vs sorafenib	PD-1	OS	Phase III
NCT02519348	Durvalumab + tremelimumab vs durvalumab monotherapy	PD-L1/CTLA-4	Adverse events	Phase II
NCT03298451	Durvalumab vs durvalumab + tremelimumab vs sorafenib HIMALAYA	PD-L1/CTLA-4	OS	Phase III
NCT01658878	Nivolumab vs nivolumab + ipilimumab vs sorafenib	PD-L1/CTLA-4	ORR	Phase I/II

PD-1 programmed cell death protein-1, PD-L1 programmed death-ligand 1, CTLA-4 cytotoxic T-lymphocyte-associated protein-4, OS overall survival, PFS progression free survival, ORR overall response rate